Keyword: Medivation

Sanofi is out another potential buyer for its European generics business as India-based Torrent Pharma exited deal talks, according to a report.

Sanofi didn't just woo Bioverativ execs. It made a play with investor Alex Denner. The result? $85M for CEO John Cox and a 2018 EPS boost for Sanofi.

Johnson & Johnson's prostate cancer drug Zytiga lost a key patent challenge that clears the way for cheap copycats later this year.

Kite investors are set for big gains with Gilead Sciences’ $180-per-share buyout—and founder Arie Belldegrun will reap a $597 million of that payday.

Pfizer announced mixed results in its second quarter, marked by a revenue shortfall on two aging blockbusters.

There is troubling news for Pfizer and cancer med Xtandi. Pfizer and partner Astellas have given up trials of Xtandi in breast cancer.

In lowering their rating, analysts with Credit Suisse highlighted some concerns with Pfizer's business going forward.

Last summer’s most ballyhooed M&A deal—Pfizer’s $14 billion buyout of Medivation—doesn’t look so impressive anymore, thanks to data rolled out at ASCO.